AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04260269
Drug: Fluoropyrimidine
RxNorm normalized name: Fluoropyrimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the assessment of a specific evaluation of cardiac safety for patients with solid tumors who have experienced cardiotoxicity grade 1-4 during treatment with a fluoropyrimidine based treatment and are re-challenged with a different fluoropyrimidine.~This multicentre, retrospective database is built to assess the impact on the cardiac and global safety of two different fluoropyrimidine based treatment regimens, of which the first has caused cardiotoxicity grade 1-4.~Cardiac data will be collected by medical record review from initiation of first fluoropyrimidine-based treatment and switch to second fluoropyrimidine-based treatment until death or last follow-up. Basic demographics, cancer and treatment information from the whole course of cancer until death or last follow-up.
Trial: NCT01216046
Drug: VX-809 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, taken once daily
Trial: NCT01216046
Drug: VX-770 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, taken once every 12 hours
Trial: NCT02502721
Drug: DWC20151
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02502721
Drug: DWC20152
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03502694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo tablets orally.
Trial: NCT00546494
Drug: Effexor® (Venlafaxine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00513266
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00513266
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01914965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
Trial: NCT04659317
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated placebo tablets x24, to take po q6 hours as need for pain
Trial: NCT00281983
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00281983
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03142893
Drug: Cosyntropin Injectable Product
RxNorm normalized name: cosyntropin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cosyntropin injection is given twice per Inpatient Stay
Trial: NCT03142893
Drug: Hydrocortisone Injection
RxNorm normalized name: hydrocortisone Injection
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone IV push is given twice per Inpatient Visit
Trial: NCT03142893
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for ketoconazole are given 4 times per Inpatient Stay
Trial: NCT01701505
Drug: 400uL of Kovacaine Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 unilateral intranasal sprays of 200uL each.
Trial: NCT01701505
Drug: 200uL of Kovacaine Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 unilateral intranasal sprays of 100uL each.
Trial: NCT00862225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
Trial: NCT00862225
Drug: IG-RD-001 / Ze 339
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
Trial: NCT04246502
Drug: Capecitabine and Pyrotinib
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pyrotinib 400mg orally daily until progressive disease
Trial: NCT00970424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, oral tablet administered once daily on background of pioglitazone
Trial: NCT00583102
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
Trial: NCT00002471
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002471
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002471
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002471
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004982
Drug: Combination Iron Chelation Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001436
Drug: OncoLAR® (Registered Trademark)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05871489
Drug: Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
Trial: NCT05871489
Drug: Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
Trial: NCT02411253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
Trial: NCT01037699
Drug: rFSH: Follicle Stimulating Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002792
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002792
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03708744
Drug: A: M207 3.8mg, 30 min, upper arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
Trial: NCT03708744
Drug: B: M207 3.8 mg, 30 min, thigh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
Trial: NCT03708744
Drug: C: M207 3.8 mg, 1 hr, upper arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
Trial: NCT00610194
Drug: RDEA119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
Trial: NCT01050699
Drug: Midazolam and Fentanyl
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)
Trial: NCT02648659
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500mg 1tablet bid(2times/day)
Trial: NCT00101062
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02475499
Drug: Sulfonylureas
RxNorm normalized name: Sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Trial: NCT02475499
Drug: Thiazolidinediones
RxNorm normalized name: Thiazolidinediones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Trial: NCT02475499
Drug: Alpha-glucosidase inhibitors
RxNorm normalized name: alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Trial: NCT04609579
Drug: SNX281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.
Trial: NCT01385683
Drug: Dabigatran then dabigatran and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
Trial: NCT01385683
Drug: Clarithromycin and dabigatran then dabigatran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
Trial: NCT00913562
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one tablet rosuvastatin 10 mg per day for 12 weeks
Trial: NCT00913562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet a day for 12 weeks
Trial: NCT02137928
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
Trial: NCT04303598
Drug: FNC placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet，QD
Trial: NCT02819271
Drug: CXL-1427 Descending Dose
RxNorm normalized name: Defend II
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02815709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02526199
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant to perinerual block
Trial: NCT03937596
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral placebo during the blinded phase (10 days).
Trial: NCT00004311
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00805519
Drug: Glucosamine and chondroitin sulfate
RxNorm normalized name: Glucosamine and Chondroitin Sulfate Sodium Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
Trial: NCT00805519
Drug: glucosamine and chondroitin sulfate plus Prednisolone
RxNorm normalized name: chondroitin sulfates / glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
Trial: NCT00805519
Drug: Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
Trial: NCT03810235
Drug: Transdermal Hydrocolloid Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrocolloid placebo patches
Trial: NCT03856645
Drug: OKG-0301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
Trial: NCT02606617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
Trial: NCT01349699
Drug: endotoxin
RxNorm normalized name: Endotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
Trial: NCT01349699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol.
Trial: NCT02372942
Drug: Lattoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 515 pregnant women using lattoferrin to prevent preterm delivery
Trial: NCT03071874
Drug: AZD2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2014 is a dual mTORC1/mTORC2 inhibitor
Trial: NCT02418819
Drug: PF-06412562 3mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06412562
Trial: NCT02418819
Drug: PF-06412562 9mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06412562
Trial: NCT02418819
Drug: PF-06412562 45mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06412562
Trial: NCT00782353
Drug: ANA598 400 mg bid or placebo
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANA598 400 mg bid or placebo
Trial: NCT03530345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glass vials with matching placebo.
Trial: NCT00586430
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of placebo
Trial: NCT03813602
Drug: Cannabis Sativa
RxNorm normalized name: CANNABIS SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg cannabis cigarette with 12.5% THC
Trial: NCT03216915
Drug: Gilenya®; Novartis Pharmaceuticals Corporation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.
Trial: NCT01786551
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg daily for 14 days
Trial: NCT02173756
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
Trial: NCT03669965
Drug: KRT-232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRT-232, administered by mouth
Trial: NCT00315042
Drug: Telithromycin (HMR3647)
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02005627
Drug: Grazax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
Trial: NCT00744406
Drug: Antidepressant medication (sertraline ,paroxetineor or venlafaxine)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
Trial: NCT01589809
Drug: nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose-escalation, 2-8 grams, oral
Trial: NCT01550107
Drug: Lactose tablets
RxNorm normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo tablets b.d
Trial: NCT02534129
Drug: Difinsa53
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difinsa53 cream is applied to one half of radiation field
Trial: NCT00640185
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take up to two 40 mg tablets once daily for 8 weeks.
Trial: NCT00640185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take one or two placebos once daily for the duration of the study.
Trial: NCT01755247
Drug: 8% NVN1000 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01755247
Drug: 8% NVN1000 Topical Gel and moisturizer
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02290379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo
Trial: NCT04599855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be self administered as nasal spray.
Trial: NCT03887429
Drug: SXC-2023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SXC-2023 oral capsules
Trial: NCT03887429
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo oral capsules
Trial: NCT01544192
Drug: Gingko Biloba
RxNorm normalized name: Gingko Biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
Trial: NCT01544192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group did not receive oral neuroprotective agent
Trial: NCT01544192
Drug: Antioxidant formula
RxNorm normalized name: Antioxidant Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x1 tablet AOF
Trial: NCT00606346
Drug: No Biologics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments will be prescribed according to investigator judgement.
Trial: NCT00694720
Drug: AVE0657
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules once a day at bedtime
Trial: NCT00694720
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules once a day at bedtime
Trial: NCT01869569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
Trial: NCT00195494
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2
Trial: NCT00195494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
Trial: NCT00819572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00513357
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg by mouth daily for 4 Weeks
Trial: NCT00513357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule by mouth daily for 4 Weeks
Trial: NCT02762500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no